WallStreetZenWallStreetZen

NASDAQ: KARD
Kardigan Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for KARD

Based on 7 analysts offering 12 month price targets for Kardigan Inc

Min Forecast
$25.00+74.58%
Avg Forecast
$41.00+186.31%
Max Forecast
$50.00+249.16%

Should I buy or sell KARD stock?

Based on 8 analysts offering ratings for Kardigan Inc.

Strong Buy
Strong Buy
5 analysts 62.5%
Buy
3 analysts 37.5%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although KARD's forecast from analysts indicates a "Strong Buy", our proven Zen Rating quant model rates KARD as a "Sell". Stocks with a Zen Rating of Sell have had an average return of -6.47% per year. Learn More

Be the first to know when Wall Street analysts revise their KARD stock forecasts and price targets.

KARD stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2026-10-29
lockedlocked$00.00+00.00%2026-10-22
lockedlocked$00.00+00.00%2026-10-16
lockedlocked$00.00+00.00%2026-10-12
lockedlocked$00.00+00.00%2026-08-25
TD Cowen
Bottom 8%
8
Strong BuyInitiates Coverage On$46.00+223.72%2026-07-13Find out why
Leerink Partners
Bottom 3%
3
BuyInitiates Coverage On$37.00+160.38%2026-07-13
Jefferies
Bottom 10%
10
Strong BuyInitiates Coverage On$40.00+181.49%2026-07-13Find out why

1 of 1

Forecast return on equity

Is KARD forecast to generate an efficient return?

Company
-57.08%
Industry
-15.38%
Market
153.17%
KARD's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is KARD forecast to generate an efficient return on assets?

Company
-48.68%
Industry
-3.58%
KARD is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

KARD earnings per share forecast

What is KARD's earnings per share in the next 3 years based on estimates from 10 analysts?

Avg 1 year Forecast
-$4.83
Avg 2 year Forecast
-$3.64
Avg 3 year Forecast
-$3.76

KARD revenue forecast

What is KARD's revenue in the next 3 years based on estimates from 9 analysts?

Avg 1 year Forecast
$0.0
Avg 2 year Forecast
$0.0
Avg 3 year Forecast
$0.0

KARD vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
KARD$14.21$41.00+188.53%Strong Buy
DMRA$21.60$48.75+125.69%Strong Buy
TSHA$4.00$12.29+207.15%Strong Buy
OMER$17.83$27.50+54.23%Strong Buy
MLYS$15.55$42.50+173.31%Buy
View Top Biotech Stocks

Kardigan Stock Forecast FAQ

Is Kardigan Stock a good buy in 2026, according to Wall Street analysts?

The consensus among 8 Wall Street analysts covering (NASDAQ: KARD) stock is to Strong Buy KARD stock.

Out of 8 analysts, 5 (62.5%) are recommending KARD as a Strong Buy, 3 (37.5%) are recommending KARD as a Buy, 0 (0%) are recommending KARD as a Hold, 0 (0%) are recommending KARD as a Sell, and 0 (0%) are recommending KARD as a Strong Sell.

If you're new to stock investing, here's how to buy Kardigan stock.

What is KARD's earnings growth forecast for 2026-2028?

(NASDAQ: KARD) Kardigan's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 14.97%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 67.33%.

Kardigan's earnings in 2026 is N/A.On average, 10 Wall Street analysts forecast KARD's earnings for 2026 to be -$451,660,268, with the lowest KARD earnings forecast at -$594,702,226, and the highest KARD earnings forecast at -$337,735,361. On average, 10 Wall Street analysts forecast KARD's earnings for 2027 to be -$340,007,501, with the lowest KARD earnings forecast at -$519,562,654, and the highest KARD earnings forecast at -$201,266,712.

In 2028, KARD is forecast to generate -$351,358,850 in earnings, with the lowest earnings forecast at -$472,829,505 and the highest earnings forecast at -$196,357,768.

What is KARD's revenue growth forecast for 2026-2028?

(NASDAQ: KARD) Kardigan's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 42.14%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.48%.

Kardigan's revenue in 2026 is N/A.On average, 9 Wall Street analysts forecast KARD's revenue for 2026 to be $0, with the lowest KARD revenue forecast at $0, and the highest KARD revenue forecast at $0. On average, 9 Wall Street analysts forecast KARD's revenue for 2027 to be $0, with the lowest KARD revenue forecast at $0, and the highest KARD revenue forecast at $0.

In 2028, KARD is forecast to generate $0 in revenue, with the lowest revenue forecast at $0 and the highest revenue forecast at $0.

What is KARD's forecast return on assets (ROA) for 2026-2028?

(NASDAQ: KARD) forecast ROA is -48.68%, which is lower than the forecast US Biotechnology industry average of -3.07%.

What is KARD's Price Target?

According to 7 Wall Street analysts that have issued a 1 year KARD price target, the average KARD price target is $41.00, with the highest KARD stock price forecast at $50.00 and the lowest KARD stock price forecast at $25.00.

On average, Wall Street analysts predict that Kardigan's share price could reach $41.00 by Oct 29, 2027. The average Kardigan stock price prediction forecasts a potential upside of 188.53% from the current KARD share price of $14.21.

What is KARD's Earnings Per Share (EPS) forecast for 2026-2028?

(NASDAQ: KARD) Kardigan's current Earnings Per Share (EPS) is N/A. On average, analysts forecast that KARD's EPS will be -$4.83 for 2026, with the lowest EPS forecast at -$6.36, and the highest EPS forecast at -$3.61. On average, analysts forecast that KARD's EPS will be -$3.64 for 2027, with the lowest EPS forecast at -$5.56, and the highest EPS forecast at -$2.15. In 2028, KARD's EPS is forecast to hit -$3.76 (min: -$5.06, max: -$2.10).

What is KARD's forecast return on equity (ROE) for 2026-2028?

(NASDAQ: KARD) forecast ROE is -57.08%, which is considered weak.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.